Regeneron Pharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 2,104,745 1,378,477 445,824 459,074
Cost of Revenue 155,355 84,455 4,216 2,093
Gross Profit 1,949,390 1,294,022 441,608 456,981
Operating Expenses
Research and Development 859,947 625,554 529,506 489,252
Sales, General and Admin. 329,415 210,755 117,261 65,201
Non-Recurring Items - - - -
Other - - - -
Operating Income 760,028 457,713 (205,159) (97,472)
Income From Continuing Operations
Add'l Income/Expense Items (231) 2,012 3,549 2,122
Earnings Before Interest and Tax 759,797 459,725 (201,610) (95,350)
Interest Expense 46,437 45,304 21,282 9,118
Earnings Before Tax 713,360 414,421 (222,892) (104,468)
Income Tax 288,998 (335,848) (1,132) -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations 424,362 750,269 (221,760) (104,468)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 424,362 750,269 (221,760) (104,468)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 424,362 750,269 (221,760) (104,468)